Arcturus Therapeutics: Q3 Earnings Insights

Arcturus Therapeutics (NASDAQ:ARCT) reported its Q3 earnings results on Tuesday, November 14, 2023 at 04:01 PM. Here’s what…

Arcturus Therapeutics (NASDAQ:ARCT) reported its Q3 earnings results on Tuesday, November 14, 2023 at 04:01 PM.

Here’s what investors need to know about the announcement.

Earnings

Arcturus Therapeutics beat estimated earnings by 63.91%, reporting an EPS of $-0.61 versus an estimate of $-1.69.

Revenue was up $31.77 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $1.77 which was followed by a 19.22% drop in the share price the next day.

Here’s a look at Arcturus Therapeutics’s past performance:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.21 0.06 0.98 -1.81
EPS Actual -1.98 0.62 4.33 -1.33
Revenue Estimate 48.50M 37.94M 72.68M 3.42M
Revenue Actual 10.52M 80.28M 160.29M 13.37M

To track all earnings releases for Arcturus Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Gatos Silver Files Financial Results For The First Three Quarters Of 2022 And Announces Investor Conference Call For 2022 Year-End Results; Net Income For First Three Months Ended September 30, 2022 $0.26/Share; Revenue $218.7M Up 23% YoY

Gatos Silver, Inc. (TSX:GATO) ("Gatos Silver" or the "Company") today filed its quarterly reports on Forms 10-Q for the quarters ended March 31, June 30, and September 30, 2022, which include its

GATO